Label-free Quantum Cascade Laser (QCL)-based infrared imaging combined with deep learning provides spatially and molecularly resolved alterations of the genome and proteome in unstained cancer tissue sections. This technique was shown to be able to distinguish between microsatellite instability-high (MSI-H) and microsatellite-stable (MSS) status of sporadic colorectal cancer (CRC) [1]. To verify the method, tissue samples from the prospective, multicentre AIO CPP registry study were analysed.
In detail, images of tissue sections taken in 20 min with QCL infrared microscopes were classified by convolutional neural networks (CNN). An in-house developed segmenting CNN (U-Net) localised tumour regions and a second CNN (VGG-Net) subsequently classified the microsatellite status. Endpoints were area under curve of receiver operating characteristic (AUROC) and area under precision recall curve (AUPRC). Dr Frederik Großerüschkamp (Ruhr-Universität Bochum, Germany) presented the results [2].
The multicentre clinical cohort included 491 patients, of which 100 tumour-free and 391 with tumour. Baseline characteristics of age, sex, stage, location, including BRAF mutation status were equally distributed among test cohorts. The U-Net was verified on 294 patients serving as training dataset, 100 as test dataset, and 97 as validation dataset. An AUROC of 0.99 was achieved for the validation dataset. Tumours are thereby precisely spatially resolved in the sections. The microsatellite status classification of the identified tumour regions was verified on 391 patients: 245 served as training dataset, 73 as test dataset, and 73 as validation dataset. In the current study, an AUROC of 0.83 and an AUPRC of 0.64 were achieved.
Based on these results, Dr Großerüschkamp concluded that “MSI-H was identified with high sensitivity but low specificity and demands therefore longer training phases and larger sample numbers for training. Both are currently under work.”
- Kallenbach-Thieltges A, et al. Sci Rep. 2020;10:10161.
- Großerüschkamp F, et al. Automated detection of microsatellite status in early colon cancer (CC) using artificial intelligence (AI) integrated infrared (IR) imaging on unstained samples from the AIO ColoPredictPlus 2.0 (CPP) registry study. Abstract 385O, ESMO Congress 2021, 16–21 September.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer Next Article
Adagrasib shows promising clinical activity in heavily pretreated KRAS-mutated CRC »
« Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer Next Article
Adagrasib shows promising clinical activity in heavily pretreated KRAS-mutated CRC »
Table of Contents: ESMO 2021
Featured articles
Breast Cancer
Trastuzumab deruxtecan triples PFS
Novel conjugate meets primary endpoint
Longest survival benefit from first-line CDK4/6 inhibitor
Meta-analysis shows 6-months adjuvant trastuzumab is optimal
Double-positive results for triple-negative metastatic breast cancer
Survival after neoadjuvant therapy with trastuzumab-lapatinib plus chemotherapy
Postmenopausal breast cancer: extended letrozole reduces recurrence
Asian women also benefit from palbociclib plus letrozole
No PEARLs of survival with palbociclib plus endocrine therapy compared with capecitabine, but QoL better
Gastrointestinal Cancer
Neoadjuvant chemotherapy potential alternative to neoadjuvant chemoradiotherapy in LARC
Immune chemo-sensitisation looks promising in microsatellite-stable mCRC
Adagrasib shows promising clinical activity in heavily pretreated KRAS-mutated CRC
Automated detection of microsatellite status on unstained samples in early colon cancer
Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer
HIPEC in gastric cancer with peritoneal metastases
ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer
Lung Cancer
Robust anticancer activity of trastuzumab deruxtecan in HER2-mutated NSCLC
Nivolumab/ipilimumab continues to provide survival benefit in unresectable MPM
Adjuvant atezolizumab lowers relapse rate in resected NSCLC
Three-year OS follow-up from CASPIAN trial
TCR clonality predicts pembrolizumab response in NSCLC
Melanoma
Adjuvant immunotherapy reduces risk of disease recurrence in stage II melanoma
IFN-γ signature predicts response to immunotherapy
Updated results of SECOMBIT trial
Combining T-VEC and pembrolizumab does not significantly improve survival in advanced, unresectable melanoma
Durable intracranial responses with nivolumab/ipilimumab
Genitourinary Cancer
TKI drug-free interval strategy not detrimental to conventional continuation strategy in RCC
Modified ipilimumab schedule reduces risk of grade 3/4 adverse events
Optimal neoadjuvant dose ipilimumab/nivolumab in stage III urothelial cancer
Better survival with neoadjuvant dose-dense MVAC regimen in MIBC
PARP inhibitor rechallenge improves PFS in ovarian cancer
Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer
Pembrolizumab has durable effect in previously treated MSI-H/dMMR advanced endometrial cancer
HRR mutational status is prognostic and predictive biomarker olaparib activity
Haematological Cancer
Mutational analyses are predictive in malignant lymphomas
Low numbers of M2 macrophages in tumour microenvironment associated with superior response to immunotherapy in Hodgkin lymphoma
COVID-19
Adequate response to SARS-CoV-2 vaccine in cancer patients
Cancer patients more likely to die from COVID-19 when hospital admittance is required
Third global survey of the ESMO Resilience Task Force
High COVID-19 mortality in Swiss cancer patients
Basic Science & Translational Research
Neutrophils negatively correlate with response to anti-PD-1 monotherapy in dMMR tumours
Tetraspecific ANKETs harnesses innate immunity in cancer therapies
Early ctDNA reduction in metastatic uveal melanoma correlates better with OS than RECIST response
Gut microbiota as a potential predictive biomarker
Related Articles
November 19, 2021
High COVID-19 mortality in Swiss cancer patients
October 4, 2021
ESMO 2021 Highlights Podcast
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com